Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis

Roberts, Lynden J., Cleland, Leslie G., Thomas, Ranjeny and Proudman, Susanna M. (2006) Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. Medical Journal of Australia, 184 3: 122-125.


Author Roberts, Lynden J.
Cleland, Leslie G.
Thomas, Ranjeny
Proudman, Susanna M.
Title Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis
Journal name Medical Journal of Australia   Check publisher's open access policy
ISSN 0025-729X
1326-5377
Publication date 2006-02-01
Sub-type Article (original research)
Volume 184
Issue 3
Start page 122
End page 125
Total pages 4
Editor M. van der Weyden
Place of publication Sydney
Publisher Australasian Medical Publishing Company Ltd
Collection year 2006
Language eng
Subject C1
321028 Rheumatology and Arthritis
730114 Skeletal system and disorders (incl. arthritis)
Abstract Most people presenting with rheumatoid arthritis today can expect to achieve disease suppression, can avoid or substantially delay joint damage and deformities, and can maintain a good quality of life. Optimal management requires early diagnosis and treatment, usually with combinations of conventional disease modifying antirheumatic drugs (DMARDs). If these do not effect remission, biological DMARDs may be beneficial. Lack of recognition of the early signs of rheumatoid arthritis, ignorance of the benefits of early application of modern treatment regimens, and avoidable delays in securing specialist appointments may hinder achievement of best outcomes for many patients. Triage for recognising possible early rheumatoid arthritis must begin in primary care settings with the following pattern of presentation as a guide: involvement of three or more joints; early-morning joint stiffness of greater than 30 minutes; or bilateral squeeze tenderness at metacarpophalangeal or metatarsophalangeal joints.
Keyword Medicine, General & Internal
Randomized Controlled-trial
Placebo-controlled Trial
Early Inflammatory Arthritis
Antitumor Necrosis Factor
Double-blind
Concomitant Methotrexate
Monoclonal-antibody
Multicenter Trial
Joint Damage
Therapy
Q-Index Code C1

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 18:39:39 EST